Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Leases (2021 - 2026)

Zentalis Pharmaceuticals has reported Leases over the past 6 years, most recently at $25.6 million for Q1 2026.

  • For Q1 2026, Leases fell 19.83% year-over-year to $25.6 million; the TTM value through Mar 2026 reached $25.6 million, down 19.83%, while the annual FY2025 figure was $26.3 million, 19.24% down from the prior year.
  • Leases for Q1 2026 was $25.6 million at Zentalis Pharmaceuticals, down from $26.3 million in the prior quarter.
  • Over five years, Leases peaked at $43.6 million in Q1 2022 and troughed at $25.6 million in Q1 2026.
  • A 5-year average of $35.1 million and a median of $34.7 million in 2024 define the central range for Leases.
  • Biggest five-year swings in Leases: dropped 5.19% in 2022 and later dropped 19.83% in 2026.
  • Year by year, Leases stood at $42.4 million in 2022, then fell by 15.24% to $35.9 million in 2023, then fell by 9.43% to $32.5 million in 2024, then dropped by 19.24% to $26.3 million in 2025, then fell by 2.57% to $25.6 million in 2026.
  • Business Quant data shows Leases for ZNTL at $25.6 million in Q1 2026, $26.3 million in Q4 2025, and $30.2 million in Q3 2025.